Updates are available Correction dated 2025-04-21

Article History

Received: 16 August 2023

Revised: 31 October 2023

Accepted: 16 November 2023

First Online: 6 January 2024

Change Date: 17 April 2025

Change Type: Update

Change Details: The original online version of this article was revised due to incorrect term “serine 205” in the section Materials and methods under the subsection Simoa CSF p-tau202 and p-tau205 measurements. Now, it has been corrected to “threonine 205”.

Change Date: 21 April 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00401-025-02877-4

Declarations

:

: KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JLR, LMG, ALB, AV, JD, EC, WSB, NR, JS, SS, JT, BB, GB, AS, HH, HK, NJA, CP and PRN report no conflicts of interest.